Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel abstracts at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference, taking place January 30 to February 1 in San Francisco. The studies were employed to evaluate Epic's circulating tumor cell (CTC) technology platform across several parameters in metastatic castration resistant prostate cancer (mCRPC). These parameters include sensitivity, specificity, pharmacodynamics and heterogeneity for use in patient selection and monitoring of clinical trials.
The six abstracts will be presented in ASCO GU General Poster Sessions A & B on January 30 and 31:
- Abstract #78: Sequential monitoring and characterization of circulating tumor cells (CTCs) using the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
- Abstract #132: Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).
- Abstract #177: Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
- Abstract #198: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).
- Abstract #209: CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).
- Abstract #266: Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer.